A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma


Full Title

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein


The normal (“wild type”) form of the p53 protein works as a tumor suppressor, putting the brakes on rampant cell growth. In lymphoma cells, two proteins called MDM2 and MDMX can inhibit p53, letting lymphoma cell growth continue. ALRN-6924 is an investigational drug designed to interfere with the interaction between MDM2, MDMX, and p53, restoring the tumor-inhibiting action of p53.

In this study, researchers are evaluating the safety and effectiveness of ALRN-6924 in patients with peripheral T-cell lymphoma that has come back or continued to grow despite prior therapy. ALRN-6924 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have peripheral T-cell lymphoma that has come back or continued to grow despite previous treatment.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Steven Horwitz at 212-639-3045.